Treatment of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy: First-Line Protocol
Clinical Scenario
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a hereditary epilepsy syndrome in which brief motor seizures cluster during sleep. This protocol covers the first-line pharmacological approach for ADNFLE.
Treatment Goals
The primary targets are complete abolition of nocturnal seizures and, where full remission is not attained, at least a 50% reduction in nocturnal seizure frequency.
Treatment Approach
Carbamazepine is the well-established drug of choice for ADNFLE — the full dosing schedule, regimen details, and clinical decision pathway are available in the complete protocol.
Full protocol details, including dosing and sequencing, available below…
References
DOI: 10.1007/s11910-013-0424-6
- Many and early reports documented carbamazepine as the drug of choice in NFLE/ADNFLE patients, and basic studies of ADNFLE mutations suggested that mutated nAChR receptors demonstrate an increased sensitivity to carbamazepine.
- According to the literature, about two thirds of NFLE/ADNFLE patients benefit from carbamazepine administration.
- This drug is usually given at low doses (200–1,000 mg at bedtime), abolishing seizures in ~20% of cases, and giving significant relief (at least 50% seizure reduction) in another 48%.
View source ↗